Attention is focusing on whether HK inno. N's new drug K-CAB for gastroesophageal reflux disease will succeed in providing additional indications. Currently, K-CAB is being reimbursed to treat erosive and non-erosive gastroesophageal reflux disease and gastric ulcer. In March 2019, K-CAB, which was first applied to the treatment of erosive and non-erosive gastroesophageal reflux disease, expanded its salary to the treatment of gastric ulcers in October last year.

According to industries on the 17th, the HIRA has started reviewing the benefit standards for K-CAB. K-CAB has acquired a total of five indications so far. Among them, health insurance benefits are applied to three treatments: erosive and non-e